Dermal dendrocytes FXIIIA+ phagocytizing extruded mast cell granules in drug-induced acute urticaria
Carregando...
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2013
Editora
WILEY-BLACKWELL
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, v.27, n.1, p.e105-e112, 2013
Resumo
Background Few authors have been attempting between mast cells and dermal dendrocytes interactions on urticaria. Objective To describe the extruded mast cell granules and dermal dendrocytes in drug-induced acute urticaria. Methods Seven patients with drug-induced acute urticaria were enrolled in the study. We token skin biopsies of urticaria lesion and perilesional skin. The 14 fragments collected were processed to immunogold electron microscopy using single stains to tryptase and FXIIIa, besides double immunogold labeling with both. Results Some sections demonstrated mast cells in degranulation process, both in anaphylactic and piecemeal degranulation types. After double immunogold staining, 10 nm (FXIIIa) and 15 nm (Tryptase) gold particles were present together over the granules in mast cells indicating that tryptase and FXIIIa are each localized within the granules of these cells. Interestingly, we found a strong evidence of than the exocytosed mast cell granules contents both FXIIIa and tryptase immunolabeled are phagocytized by dermal dendrocytes. Conclusions The current observations provide morphological evidence that the exocytosis-phagocytosis mechanisms of mast cell granules represents one pathophysiological example of mast cells-dermal dendrocytes interactions in urticaria.
Palavras-chave
Referências
- Adany R, 2001, THROMB HAEMOSTASIS, V85, P845
- BAGGIOLINI M, 1982, INT ARCH ALLER A IMM, V67, P219
- Becherel PA, 1997, MOL MED, V3, P686
- Benahmed S, 2005, ARCH INTERN MED, V165, P1500, DOI 10.1001/archinte.165.13.1500
- Caproni M, 2005, CLIN IMMUNOL, V114, P284, DOI 10.1016/j.clim.2004.10.007
- Caproni M, 2006, INT J IMMUNOPATH PH, V19, P507
- CRAIG SS, 1988, LAB INVEST, V58, P682
- Criado PR, 2006, J EUR ACAD DERMATOL, V20, P1095, DOI 10.1111/j.1468-3083.2006.01744.x
- Criado RFJ, 2008, J DERMATOL TREAT, V19, P92, DOI 10.1080/09546630701499309
- Cugno M, 2009, INT ARCH ALLERGY IMM, V148, P170, DOI 10.1159/000155748
- CZARNETZKI BM, 1990, ARCH DERMATOL RES, V282, P93, DOI 10.1007/BF00493465
- Decorti G, 2000, TOXICOL APPL PHARM, V169, P269, DOI 10.1006/taap.2000.9072
- Haas N, 1998, ARCH DERMATOL, V134, P41, DOI 10.1001/archderm.134.1.41
- Hermanns-Le T, 1999, DERMATOLOGY, V198, P184, DOI 10.1159/000018108
- Kavanaugh A, 2005, ANN RHEUM DIS, V64, P46, DOI 10.1136/ard.2004.030817
- LINDAHL U, 1979, BIOCHEM J, V182, P189
- Monteiro MR, 1999, J INVEST DERMATOL, V113, P272, DOI 10.1046/j.1523-1747.1999.00665.x
- MOORE N, 1985, LANCET, V2, P1056
- Nestle FO, 2007, J CLIN INVEST, V117, P2382, DOI 10.1172/JC133349
- SCHAUMBURGLEVER G, 1994, J CUTAN PATHOL, V21, P129, DOI 10.1111/j.1600-0560.1994.tb00247.x
- Shukla Shruti A, 2006, Methods Mol Biol, V315, P63
- Silverman JS, 2003, J CUTAN PATHOL, V30, P415, DOI 10.1034/j.1600-0560.2003.00094.x
- SUEKI H, 1993, LAB INVEST, V69, P160
- Torocsik D, 2005, CELL MOL LIFE SCI, V62, P2132, DOI 10.1007/s00018-005-5242-9